全球PET放射性示蹤劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計 PET 放射性追蹤劑市場將從 2025 年的 26.3 億美元成長到 2034 年的 56.5 億美元，2026 年至 2034 年的複合年成長率為 8.84%。

由於正子斷層掃描（PET）在腫瘤學、神經病學和心臟病學診斷的應用日益廣泛，全球PET放射性示蹤劑市場正在擴張。全球癌症發生率的上升以及對後續觀察複雜的疾病。

放射性藥物研發的進步和分子影像研究的擴展進一步增強了市場動態。核子醫學基礎設施投資的增加以及PET/CT等混合影像系統的日益普及，也推動了市場需求的成長。此外，正在進行的探索新型標靶成像示蹤劑的臨床研究，也擴大了放射性藥物的應用範圍。

隨著個人化醫療和精準診斷的重要性日益凸顯，未來前景一片光明。開發具有更高特異性和更短半衰期的新型示蹤劑將提升臨床療效。隨著醫療系統持續投資於先進診斷技術，PET放射性追蹤劑市場預計將在全球範圍內保持持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球PET放射性示蹤劑市場：依放射性示蹤劑類型分類

• 市場分析、洞察與預測
• F-18（FDG18）
• Ga-68（FAPI）
• 其他

第5章 全球PET放射性示蹤劑市場：依應用分類

• 市場分析、洞察與預測
• 癌症
• 心臟病
• 消化器官系統
• 內分泌
• 神經系統疾病
• 其他

第6章 全球PET放射性示蹤劑市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 診斷中心
• 其他

第7章 全球PET放射性示蹤劑市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • ABX Advanced Biochemical Compounds GmbH（Cambridge Isotope Laboratories Inc.）
  • Blue Earth Diagnostics
  • Cardinal Health
  • Eli Lilly And Company
  • GE Healthcare
  • IBA Radiopharma Solutions
  • Jubilant Pharma Limited
  • Lantheus Holdings Inc
  • Siemens Healthineers AG
  • Yantai Dongcheng Pharmaceutical Group Co. Ltd

The PET Radiotracer Market size is expected to reach USD 5.65 Billion in 2034 from USD 2.63 Billion (2025) growing at a CAGR of 8.84% during 2026-2034.

The global PET radiotracer market is expanding due to the increasing use of positron emission tomography in oncology, neurology, and cardiology diagnostics. Growing cancer incidence worldwide and rising demand for early disease detection are major drivers supporting market growth. PET radiotracers enable high-precision imaging, helping physicians diagnose and monitor complex medical conditions effectively.

Advancements in radiopharmaceutical development and growing research in molecular imaging are further strengthening market dynamics. Increased investments in nuclear medicine infrastructure and rising adoption of hybrid imaging systems such as PET/CT are contributing to demand expansion. Additionally, ongoing clinical research exploring new tracers for targeted imaging is broadening application scope.

Future prospects appear promising as personalized medicine and precision diagnostics gain importance. Development of novel tracers with improved specificity and shorter half-lives will enhance clinical efficiency. As healthcare systems continue investing in advanced diagnostic technologies, the PET radiotracer market is expected to witness sustained growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Radiotracer Type

• F-18 (FDG18)
• Ga-68 (FAPI)
• Others

By Application

• Cancer
• Heart Disease
• Gastrointestinal
• Endocrine
• Neurological Disorders
• Others

By End-user

• Hospitals
• Diagnostic Centers
• Others

COMPANIES PROFILED

• ABX advanced biochemical compounds GmbH Cambridge Isotope Laboratories Inc, Blue Earth Diagnostics, Cardinal Health, Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc, Siemens Healthineers AG, Yantai Dongcheng Pharmaceutical Group Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PET RADIOTRACER MARKET: BY RADIOTRACER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Radiotracer Type
• 4.2. F-18 (FDG18) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ga-68 (FAPI) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PET RADIOTRACER MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Heart Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Endocrine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PET RADIOTRACER MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PET RADIOTRACER MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Radiotracer Type
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Radiotracer Type
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Radiotracer Type
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Radiotracer Type
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Radiotracer Type
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PET RADIOTRACER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.)
  • 9.2.2 Blue Earth Diagnostics
  • 9.2.3 Cardinal Health
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 GE Healthcare
  • 9.2.6 IBA Radiopharma Solutions
  • 9.2.7 Jubilant Pharma Limited
  • 9.2.8 Lantheus Holdings Inc
  • 9.2.9 Siemens Healthineers AG
  • 9.2.10 Yantai Dongcheng Pharmaceutical Group Co. Ltd